Creating RNA vaccines to help treat peanut allergies
Official title: Developing RNA Vaccines to Treat Peanut Hypersensitivity
Funded at Duke University · NIH-10800706 · Data updated 2026-11-12
This study is working on a new type of vaccine that uses mRNA technology to help people with peanut allergies by creating safer versions of peanut proteins, aiming to reduce allergic reactions and provide a better option than current treatments.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | March 3, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $200,490 |
| NIH project number | 5R21AI173486-02 |
| Project ID | NIH-10800706 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with a diagnosed peanut allergy who are seeking new treatment options.
✕Less likely to help
Patients without a peanut allergy or those who are not hypersensitive to peanuts may not benefit from this research.
What this research studies
This research aims to develop innovative RNA vaccines that target peanut allergies by using mRNA technology to create hypoallergenic peanut proteins. These vaccines are designed to express modified versions of the peanut allergen Ara h 2, which is known to trigger allergic reactions in sensitive individuals. By disrupting the specific IgE epitopes that cause these reactions, the goal is to provide a safer alternative to current oral immunotherapy methods, which can lead to severe allergic responses. The research will involve laboratory tests to assess the effectiveness and safety of these vaccines in preventing allergic reactions.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for individuals with peanut allergies, reducing the risk of severe allergic reactions.
How similar studies have gone: While the use of mRNA technology in vaccines has shown success in other areas, this specific application for peanut allergies is novel and has not been extensively tested.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Johnson-Weaver, Brandi — Duke University
- Study coordinator: Johnson-Weaver, Brandi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.